Viral Load Suppression Among Adults with HIV on Antiretroviral Therapy: Outcomes from a Lusaka District Hospital, Zambia

Authors

  • Lillian Lamba School of Medicine and Health Sciences, University of Lusaka, P.O. Box 36711, Lusaka. Zambia
  • Eustarckio Kazonga Department of Public Health, School of Medicine and Health Sciences, University of Lusaka, Lusaka, Zambia
  • Christopher Nyirenda Department of Clinical Sciences, School of Medicine, Copperbelt University/Ndola Teaching Hospital, Ndola, Zambia
  • Rodgers Chilyabanyama Churches Health Association of Zambia, Lusaka, Zambia; 5 Zambia National Public Health Institute, Lusaka, Zambia.

DOI:

https://doi.org/10.25259/IJTMRPH_4_2023

Keywords:

  • Anti-Retroviral Therapy,
  • Human Immunodeficiency Virus,
  • Multi-Month Dispensation,
  • Regimens,
  • Viral Load

Abstract

Background and Objective: HIV/AIDS remains a major public health issue, worldwide, ranking among the top 10 causes of death, particularly in low-income countries. The objective of this research was to determine factors that influence viral suppression in HIV-positive individuals aged 15 years and older who are receiving antiretroviral therapy (ART) from Chawama First-Level Hospital. Methods: A cross-sectional study design was used to investigate viral load suppression (VLS) factors in adults on ART. Data were analyzed using descriptive and inferential statistics, specifically, the Pearson Chi-square test to assess variable associations. Additionally, logistic regression was used to analyze the relationship between independent variables and the outcome variable. All statistical tests were set at a 95% confidence level (p < 0.05). Data were analyzed using STATA version 14.2, Stata Corp LP, College Station, TX. Results: Out of 10,758 participants, 10,396 (96.64%) achieved viral suppression. Factors associated with viral suppression included the 35–39 age group (AOR = 1.56, p = 0.042) and the 50-and-above age group (AOR = 2.148, p = 0.006). Those not on tenofovir, lamivudine, and dolutegravir (TLD) or tenofovir alafenamide, emtricitabine, and dolutegravir (TAFED) regimens had lower odds (AOR = 0.14, p = 0.001). Longer treatment duration also showed a positive correlation with better odds: 1 year (AOR: 5.387), 2 years (AOR: 8.18), 3 years (AOR: 8.48), 4 years (AOR: 8.37), and 5 years (AOR: 12.13), all with p < 0.001. Additionally, multi-month dispensation (MMD) further demonstrated higher odds, particularly 3–5 months (AOR = 18.257) and 6+ months (AOR = 22.137), both p < 0.001. Conclusion and Implications for Translation: The research findings suggest that different socio-demographic and clinical factors may influence viral suppression. Therefore, the study recommends that People Living with HIV (PLWHIV) adhere to ART which should be encouraged by the health workers and strengthen MMD to increase the likelihood of VLS among PLWHIV.

Downloads

Download data is not yet available.

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.

Downloads

Abstract Views: 1623
PDF Views/Downloads: 578
HTML Views/Downloads: 144

Published

2025-02-14
Dimensions Citation count:

How to Cite

Lamba, L., Kazonga, E., Nyirenda, C., & Chilyabanyama, R. (2025). Viral Load Suppression Among Adults with HIV on Antiretroviral Therapy: Outcomes from a Lusaka District Hospital, Zambia. International Journal of Translational Medical Research and Public Health, 9(Continuous), e004. https://doi.org/10.25259/IJTMRPH_4_2023

License


Copyright © 2025 Lillian Lamba, Eustarckio Kazonga, Christopher Nyirenda, Rodgers Chilyabanyama. Published by Global Health and Education Projects, Inc., USA.

Creative Commons License

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License , which permits others to remix, transform, and build upon the work non-commercially, provided the original author is credited and the new creations are licensed under the same terms.